Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Shitara, K.; Van Cutsem, E.; Lordick, F.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Xu, R. H.; Lonardi, S.; Yamaguchi, K.; Hung, Y. P.; Kukielka-Budny, B.; Bhattacharya, P. P.; Matsangou, M.; Li, R.; Moran, D. M.; Ranganath, R.; Pophale, R.; Ajani, J. A. |
| Abstract Title: | Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401012 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4036 |
| Notes: | Meeting Abstract: 4036 -- Source: Wos |
